The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc. ("Sorrento" or "the Company") (NASDAQ:SRNE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

According to the Complaint, the Company made false and misleading statements to the market. Sorrento announced an initial finding of "100% inhibition" of an in vitro virus infection, but this finding will not necessarily translate to safety or success in person or in vivo. The Company did not find a "cure" for COVID-19. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Sorrento, investors suffered damages.